Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...
Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...
The Motley Fool on MSN12d
Is Merck Stock a Buy?Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback